182 related articles for article (PubMed ID: 37892241)
1. Designing Nanomedicines for Breast Cancer Therapy.
Abbasi Dezfouli S; Rajendran AP; Claerhout J; Uludag H
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892241
[TBL] [Abstract][Full Text] [Related]
2. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
[TBL] [Abstract][Full Text] [Related]
3. Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells.
Parmar MB; K C RB; Löbenberg R; Uludağ H
Biomacromolecules; 2018 Nov; 19(11):4193-4206. PubMed ID: 30222931
[TBL] [Abstract][Full Text] [Related]
4. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
5. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
6. Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes.
Santadkha T; Skolpap W; K C R; Ansari A; Kucharski C; Atz Dick T; Uludağ H
Invest New Drugs; 2022 Oct; 40(5):962-976. PubMed ID: 35834040
[TBL] [Abstract][Full Text] [Related]
7. Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells.
Liu L; Li H; Zhang M; Lv X
Int J Clin Exp Pathol; 2015; 8(6):6674-82. PubMed ID: 26261549
[TBL] [Abstract][Full Text] [Related]
8. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
9. A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis.
Shao W; Paul A; Abbasi S; Chahal PS; Mena JA; Montes J; Kamen A; Prakash S
Int J Nanomedicine; 2012; 7():1575-86. PubMed ID: 22619514
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
[TBL] [Abstract][Full Text] [Related]
11. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
[TBL] [Abstract][Full Text] [Related]
12. Silencing of GFP expression in human mesenchymal stem cells using quaternary polyplexes of siRNA-PEI with glycosaminoglycans and albumin.
Herrera LC; Shastri VP
Acta Biomater; 2019 Nov; 99():397-411. PubMed ID: 31541736
[TBL] [Abstract][Full Text] [Related]
13. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
Thapa B; Kc R; Bahniuk M; Schmitke J; Hitt M; Lavasanifar A; Kutsch O; Seol DW; Uludag H
Hum Gene Ther; 2019 Dec; 30(12):1531-1546. PubMed ID: 31547718
[TBL] [Abstract][Full Text] [Related]
14. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).
Mohseni M; Kucharski C; K C RB; Nasrullah M; Jiang X; Uludağ H; Brandwein J
PLoS One; 2021; 16(6):e0251719. PubMed ID: 34157051
[TBL] [Abstract][Full Text] [Related]
16. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
17. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
18. Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: Effect of degree of PEG grafting on biological and cellular activity.
Safari F; Tamaddon AM; Zarghami N; Abolmali S; Akbarzadeh A
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1561-8. PubMed ID: 26232080
[TBL] [Abstract][Full Text] [Related]
19. Silica nanoparticles and polyethyleneimine (PEI)-mediated functionalization: a new method of PEI covalent attachment for siRNA delivery applications.
Buchman YK; Lellouche E; Zigdon S; Bechor M; Michaeli S; Lellouche JP
Bioconjug Chem; 2013 Dec; 24(12):2076-87. PubMed ID: 24180511
[TBL] [Abstract][Full Text] [Related]
20. siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers.
Sahin B; Fife J; Parmar MB; Valencia-Serna J; Gul-Uludağ H; Jiang X; Weinfeld M; Lavasanifar A; Uludağ H
Biomaterials; 2014 Nov; 35(34):9382-94. PubMed ID: 25128374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
